Effector, Pfizer, Merck partner to test novel immuno-oncology agents in CRC — 4 key notes

Effector Therapeutics is partnering with Pfizer and Merck to evaluate two immuno-oncology agents in patients with microsatellite stable colorectal cancer.

Here's what you should know:

1. The companies are going to conduct a phase II, open-label, randomized, non-comparative study to examine Effector's small molecule MNK1/2 inhibitor eFT508 — a cancer treatment that uses the body's immune system to fight cancer.

2. The inhibitor will be paired with avelumab in patients with relapsed or refractory CRC. The companies will also evaluate eFT508 alone as a monotherapy.

3. Researchers will randomize patients two-to-one into combo-and monotherapy arms.

4. The companies will begin the study in the third quarter of fiscal year 2017.

More articles on gastroenterology: 
AGA on Better Care Reconciliation Act: 'Patient access to care in peril'
GI center to know: University Gastroenterology
Takeda's CEO under pressure & more — 5 GI company key notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months